GO:0004879 nuclear receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004879 nuclear receptor activity is a ligand-regulated DNA-binding transcription factor activity that controls specific gene sets transcribed by RNA polymerase II.
• Nuclear receptor ligands are usually lipid-based, such as steroid hormones, and ligand binding often occurs in the cytosol before nuclear translocation.
• The activity depends on ligand binding, DNA binding, and recruitment of coregulators that modulate chromatin and transcription.
• Phosphorylation and other post-translational modifications fine-tune nuclear receptor activity in xenobiotic and endocrine signaling.
• Dysregulated nuclear receptor activity is linked to cancer, metabolic disease, and endocrine disorders, making it a major drug target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect nuclear receptor function and therapeutic potential.
Description
Nuclear receptor activity (GO:0004879) defines a DNA-binding transcription factor activity that is regulated by ligand binding and modulates the transcription of specific gene sets transcribed by RNA polymerase II. This activity is central to how cells sense lipid-soluble hormones, vitamins, and xenobiotic compounds and convert those signals into changes in gene expression. Because nuclear receptors directly bind DNA and recruit coregulators, they serve as molecular switches that connect environmental and endocrine cues to transcriptional programs. Researchers study nuclear receptor activity to understand development, metabolism, reproduction, and immune function, as well as to identify therapeutic targets for cancer and metabolic diseases. The activity is not a single protein but a functional class that includes receptors for steroids, thyroid hormone, vitamin D, retinoic acid, and many orphan receptors. Experimental dissection of this activity requires methods that measure ligand binding, DNA occupancy, coregulator recruitment, and downstream transcriptional output. In this article, we integrate the QuickGO definition with verified literature to outline the mechanism, key genes, disease relevance, and CRISPR-based research strategies for nuclear receptor activity.
nuclear receptor activity At A Glance
| GO ID | GO:0004879 |
|---|---|
| GO term | nuclear receptor activity |
| Ontology | molecular_function |
| Synonym | ligand-dependent nuclear receptor activity; nuclear hormone receptor; ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity |
| Major function | Ligand-regulated DNA-binding transcription factor activity that modulates RNA polymerase II transcription of specific gene sets |
| Ligand type | Usually lipid-based ligands such as steroid hormones, vitamin D3, retinoic acid, and thyroid hormone |
| Subcellular context | Ligand binding often occurs in the cytosol, followed by nuclear translocation |
| Coregulators | Recruitment of coactivators and corepressors is required for transcriptional regulation |
| Regulation | Activity is modulated by phosphorylation and other post-translational modifications |
What Is GO:0004879?
According to the QuickGO definition, nuclear receptor activity is a DNA-binding transcription factor activity regulated by binding to a ligand that modulates the transcription of specific gene sets transcribed by RNA polymerase II. Nuclear receptor ligands are usually lipid-based, such as a steroid hormone, and ligand binding often occurs in the cytosol, leading to translocation of the receptor to the nucleus. In practice, this means the receptor must bind a ligand, bind specific DNA response elements, and recruit coactivators or corepressors to alter RNA polymerase II transcription.
Why Is nuclear receptor activity Important in Cell Biology?
Nuclear receptor activity is essential because it converts endocrine, metabolic, and xenobiotic signals into precise transcriptional programs that control development, homeostasis, and stress responses. Many nuclear receptors are direct drug targets, and their activity is implicated in cancer, metabolic syndrome, and inflammatory diseases. Understanding this activity at the molecular level enables researchers to design selective modulators and to interpret how genetic variants alter receptor function.
• Controls gene expression programs in response to steroid hormones, vitamin D, retinoic acid, and thyroid hormone.
• Regulates development, reproduction, metabolism, and immune function through ligand-dependent transcription.
• Serves as a major drug target class for cancer, diabetes, and inflammatory diseases.
• Coregulator recruitment determines whether a receptor activates or represses transcription.
• Phosphorylation and other modifications tune receptor activity in xenobiotic and endocrine signaling.
• Dysregulation is linked to endocrine resistance, metabolic disorders, and developmental defects.
• CRISPR models enable causal testing of receptor variants and coregulator requirements.
• Nuclear receptor activity is conserved from Drosophila to humans, supporting model organism studies.
Molecular Mechanism of nuclear receptor activity
Ligand binding and activation
In simple terms: A lipid-like hormone enters the cell and binds the receptor, flipping it into an active shape.
Nuclear receptor activity begins with ligand binding, usually by lipid-based molecules such as steroid hormones, vitamin D3, or retinoic acid. Ligand binding often occurs in the cytosol and induces a conformational change that releases corepressors and promotes nuclear translocation. This step is the primary regulatory switch for receptor activity and determines target gene specificity.
DNA binding and response element recognition
In simple terms: The activated receptor finds specific DNA sequences and docks onto them.
Activated nuclear receptors bind specific DNA response elements as monomers, homodimers, or heterodimers, thereby positioning the receptor at target promoters and enhancers. DNA binding is sequence-specific and is required for recruitment of transcriptional coregulators. The DNA-binding domain and dimerization interfaces are critical for this step.
Coregulator recruitment and chromatin remodeling
In simple terms: The receptor calls in helper proteins that open or close chromatin and turn genes on or off.
Nuclear receptors recruit coactivators or corepressors that modify chromatin and bridge to the RNA polymerase II machinery. Coactivator complexes often possess histone acetyltransferase activity, while corepressor complexes recruit histone deacetylases. The balance of these coregulators determines the transcriptional output of nuclear receptor activity.
Post-translational regulation of receptor activity
In simple terms: Chemical tags on the receptor can change how strongly it works.
Phosphorylation of nuclear receptors modulates their activity, stability, and interaction with coregulators, particularly in xenobiotic signal transduction. For example, phosphorylated CAR forms a homodimer to repress its constitutive activity until ligand activation occurs. These modifications provide an additional layer of regulation beyond ligand binding.
Transcriptional output and feedback
In simple terms: The receptor turns target genes on or off, and the products of those genes can feed back on the receptor.
Once bound to DNA and coregulators, nuclear receptors modulate RNA polymerase II transcription of specific gene sets. Target genes can include metabolic enzymes, growth factors, and other transcription factors, creating feedback loops that shape the cellular response. This transcriptional output is the functional readout of nuclear receptor activity.
Key Genes Involved in GO:0004879 nuclear receptor activity
The following genes encode nuclear receptors and coregulators that are central to GO:0004879 nuclear receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR3C1 | Glucocorticoid receptor; ligand-activated transcription factor | Stress response, inflammation, and metabolic regulation |
| NR3C2 | Mineralocorticoid receptor; regulates salt and water balance | Hypertension and electrolyte disorders |
| ESR1 | Estrogen receptor alpha; mediates estrogen signaling | Breast cancer and endocrine therapy |
| ESR2 | Estrogen receptor beta; modulates estrogen responses | Reproductive biology and cancer |
| AR | Androgen receptor; mediates androgen signaling | Prostate cancer and androgen insensitivity |
| PGR | Progesterone receptor; regulates reproductive tissues | Breast and endometrial cancer |
| VDR | Vitamin D receptor; controls calcium homeostasis and immune function | Vitamin D signaling and cancer |
| RARA | Retinoic acid receptor alpha; mediates retinoid signaling | Acute promyelocytic leukemia |
| RXRA | Retinoid X receptor alpha; heterodimer partner for many nuclear receptors | Metabolic and developmental regulation |
| THRA | Thyroid hormone receptor alpha; regulates metabolism and development | Thyroid disorders and metabolic disease |
| PPARG | Peroxisome proliferator-activated receptor gamma; adipogenesis and glucose homeostasis | Diabetes and obesity |
| NR1I3 | Constitutive androstane receptor (CAR); xenobiotic sensor | Drug metabolism and xenobiotic response |
| NCOA1 | Nuclear receptor coactivator 1; enhances transcription | Coregulator function in cancer |
| NCOA2 | Nuclear receptor coactivator 2; bridges receptor and RNA polymerase II | Transcriptional regulation |
| NCOR1 | Nuclear receptor corepressor 1; represses transcription | Endocrine resistance and development |
| NCOA4 | Nuclear receptor coactivator 4; potential coactivator-independent roles | Iron metabolism and cancer |
| Rev-erb | Nuclear receptor controlling circadian and metabolic genes | Exercise adaptation and metabolism |
How Is nuclear receptor activity Regulated?
Nuclear receptor activity is regulated at multiple levels. Ligand availability and metabolism control the initial activation step. Phosphorylation by kinases modulates receptor stability, DNA binding, and coregulator recruitment, as shown for xenobiotic receptors. For example, phosphorylated CAR forms a homodimer to repress its constitutive activity until ligand activation occurs. Coregulator expression levels and post-translational modifications further tune transcriptional output. In Drosophila, MLE/DHX9 without helicase activity activates constitutive expression of nuclear receptor genes, indicating additional transcriptional regulation. Exercise and circadian factors can also influence nuclear receptor activity, as shown for Rev-erb in muscle.
nuclear receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ESR1 | Breast cancer, endocrine resistance | Knockout and point-mutation cell lines to test ligand response |
| AR | Prostate cancer, androgen insensitivity | Knock-in of patient variants in prostate cancer cells |
| NR1I3 | Drug metabolism, xenobiotic toxicity | Phosphorylation-site point mutants to study CAR activation |
| PPARG | Diabetes, obesity | Overexpression and knockout models for metabolic gene profiling |
| VDR | Vitamin D-resistant rickets, immune dysfunction | Knockout models to assess vitamin D target genes |
Cancer and endocrine resistance
Altered nuclear receptor activity is a hallmark of many cancers. Estrogen receptor alpha (ESR1) and androgen receptor (AR) drive breast and prostate cancer proliferation, and mutations or splice variants can confer resistance to endocrine therapy. Coregulator imbalances, such as altered NCOA1 or NCOR1 levels, further modulate receptor activity and treatment response. Targeting nuclear receptor activity with selective modulators remains a major therapeutic strategy.
Metabolic and cardiovascular disorders
Nuclear receptors such as PPARG, THRA, and Rev-erb regulate lipid and glucose metabolism, and their dysfunction contributes to diabetes, obesity, and cardiovascular disease. Phosphorylation of nuclear receptors can alter metabolic gene programs in response to xenobiotic exposure. Understanding these pathways supports the development of receptor-selective drugs.
Xenobiotic response and drug metabolism
The constitutive androstane receptor (CAR, NR1I3) senses xenobiotics and induces drug-metabolizing enzymes. Its activity is controlled by phosphorylation and homodimerization, which repress constitutive activity until ligand activation. Dysregulation of this pathway can affect drug efficacy and toxicity.
Developmental and reproductive disorders
Nuclear receptor activity is essential for development and reproduction. Mutations in AR cause androgen insensitivity syndrome, while disruptions in RARA are linked to acute promyelocytic leukemia. Vitamin D receptor (VDR) mutations cause hereditary vitamin D-resistant rickets. These examples highlight the clinical importance of precise receptor function.
From nuclear receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of receptor function alter target gene expression? | CRISPR knockout cell line |
| Does a specific ligand-binding mutation change receptor activity? | Point-mutation knock-in |
| Does a disease-associated variant affect transcriptional output? | Knock-in of the variant allele |
| Where is the receptor localized and how does it translocate? | Tagged knock-in with fluorescent protein |
| Does overexpression mimic ligand-independent activation? | Overexpression cell model |
| Which coregulators are required for receptor activity? | Knockout of coregulator genes followed by reporter assays |
How to Study the nuclear receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter assay | Ligand-dependent transcriptional activity | Testing receptor agonists and antagonists |
| ChIP-seq | Genome-wide DNA binding sites | Mapping nuclear receptor cistromes |
| RNA-seq | Changes in target gene expression | Transcriptional output of receptor activation |
| Phospho-immunoblotting | Receptor phosphorylation status | Studying post-translational regulation |
| CRISPR knockout screening | Genes required for receptor activity | Identifying coregulators and signaling factors |
| Proximity ligation assay | Receptor-coregulator interactions | Detecting ligand-induced complex formation |
| Fluorescence microscopy | Subcellular localization and translocation | Visualizing nuclear translocation |
| Mass spectrometry | Coregulator complex composition | Defining receptor interactomes |
Transcriptional reporter assays
Reporter assays using nuclear receptor response elements fused to luciferase are standard for measuring ligand-dependent transcriptional activity. They can be combined with CRISPR knockouts of the receptor or coregulators to test causality.
Chromatin immunoprecipitation and sequencing
ChIP-seq identifies genome-wide DNA binding sites of nuclear receptors and coregulators, revealing direct target genes and response element motifs. This method is essential for mapping the cistrome of nuclear receptor activity.
Phosphorylation and post-translational modification analysis
Phospho-specific antibodies and mass spectrometry can detect ligand-dependent phosphorylation of nuclear receptors, as shown for CAR and other xenobiotic receptors. These methods link signaling pathways to receptor activation.
CRISPR screening and functional genomics
Pooled CRISPR screens can identify genes that modify nuclear receptor activity, including coregulators and signaling components. Such screens are powerful for discovering new therapeutic targets.
How CRISPR Can Be Used to Study GO:0004879 nuclear receptor activity
Knockout
CRISPR knockout of a nuclear receptor gene eliminates its activity, allowing researchers to test which target genes and phenotypes depend on that receptor. For example, knockout of Rev-erb in muscle revealed its role in exercise adaptation. Knockout of coregulators such as NCOA1 or NCOR1 can reveal their requirement for receptor function.
Point Mutation
Point mutations can be introduced into ligand-binding or DNA-binding domains to dissect specific functions. For instance, phosphorylation-site mutations in CAR alter its homodimerization and ligand response. Such models are valuable for separating ligand-dependent from ligand-independent activities.
Knock-in
Knock-in of disease-associated variants or tagged receptors enables study of receptor function in a physiological context. Tagged knock-in allows visualization of receptor localization and translocation. Variant knock-in can reveal how mutations alter transcriptional output and drug response.
Overexpression
Overexpression of a nuclear receptor or its coregulator can amplify signaling and reveal gain-of-function phenotypes. This approach is useful for testing ligand-independent activation and for identifying downstream gene programs.
How EDITGENE Supports nuclear receptor activity Research
Researchers studying nuclear receptor activity-related genes often need to determine whether a candidate gene is causally involved in ligand-dependent transcription, coregulator recruitment, or disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services to enable these causal experiments with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for nuclear receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Ppard Knockout NIT-1 Cell Line | EDJ-KQ60 | Mouse | 19015 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| PPARD Knockout HEK293 Cell Line | EDJ-KQ115 | Human | 5467 | Details Get a Quote |
| NR4A1 Knockout HEK293 Cell Line | EDJ-KQ717 | Human | 3164 | Details Get a Quote |
| RXRA Knockout HEK293 Cell Line | EDJ-KQ864 | Human | 6256 | Details Get a Quote |
| STAT3 Knockout HEK293 Cell Line | EDJ-KQ903 | Human | 6774 | Details Get a Quote |
| ARNT Knockout HEK293 Cell Line | EDJ-KQ914 | Human | 405 | Details Get a Quote |
| PPARG Knockout HEK293 Cell Line | EDJ-KQ1115 | Human | 5468 | Details Get a Quote |
| PPARA Knockout HEK293 Cell Line | EDJ-KQ1808 | Human | 5465 | Details Get a Quote |
| HNF4A Knockout HEK293 Cell Line | EDJ-KQ1865 | Human | 3172 | Details Get a Quote |
| SREBF1 Knockout HEK293 Cell Line | EDJ-KQ1869 | Human | 6720 | Details Get a Quote |
| NR6A1 Knockout HEK293 Cell Line | EDJ-KQ1952 | Human | 2649 | Details Get a Quote |
| RORA Knockout HEK293 Cell Line | EDJ-KQ2056 | Human | 6095 | Details Get a Quote |
| NR2F2 Knockout HEK293 Cell Line | EDJ-KQ2189 | Human | 7026 | Details Get a Quote |
Displaying Records 1 To 15 Of 231 Records
- 1
- 2
- ...
- 14
- 15
- Next Page »
Frequently Asked Questions About nuclear receptor activity
What is nuclear receptor activity?
Nuclear receptor activity (GO:0004879) is a ligand-regulated DNA-binding transcription factor activity that modulates transcription of specific gene sets by RNA polymerase II.
What genes are involved in nuclear receptor activity?
Key genes include NR3C1, ESR1, AR, VDR, RARA, RXRA, PPARG, NR1I3, NCOA1, NCOA2, and NCOR1, among others.
How is nuclear receptor activity regulated?
It is regulated by ligand binding, phosphorylation, coregulator recruitment, and post-translational modifications.
What diseases are linked to nuclear receptor activity?
Cancers such as breast and prostate cancer, metabolic disorders, and developmental conditions are linked to altered nuclear receptor activity.
What is the role of coregulators in nuclear receptor activity?
Coregulators such as NCOA1 and NCOR1 are recruited by receptors to activate or repress transcription.
How can CRISPR be used to study nuclear receptor activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of receptor and coregulator function.
What methods measure nuclear receptor activity?
Reporter assays, ChIP-seq, RNA-seq, phospho-immunoblotting, and CRISPR screens are commonly used.
What is the difference between nuclear receptor activity and other transcription factor activities?
Nuclear receptor activity is specifically regulated by lipid-based ligands and often involves cytosolic-to-nuclear translocation.
Which nuclear receptors are drug targets?
ESR1, AR, PPARG, and NR1I3 are prominent drug targets for cancer and metabolic diseases.
How does phosphorylation affect nuclear receptor activity?
Phosphorylation can modulate receptor stability, DNA binding, and coregulator interactions, as shown for CAR.
Conclusion
Nuclear receptor activity (GO:0004879) is a fundamental molecular function that translates lipid-based hormonal and xenobiotic signals into specific transcriptional programs. Its regulation by ligands, phosphorylation, and coregulators makes it a central node in development, metabolism, and disease. CRISPR-based models are indispensable for dissecting the causal roles of nuclear receptors and their coregulators, and for validating therapeutic targets. EDITGENE provides comprehensive services to support these studies with precision and scale.
References
- 1. Helmstädter M et al.. 2022. Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists.. Int J Mol Sci 23(17) PMID: 36077469
- 2. Westin S et al.. 2000. Nuclear receptor coactivators.. Adv Pharmacol 47:89-112 PMID: 10582085
- 3. Negishi M et al.. 2020. Nuclear receptor phosphorylation in xenobiotic signal transduction.. J Biol Chem 295(45):15210-15225 PMID: 32788213
- 4. Kollara A et al.. 2012. Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity.. Cell Mol Life Sci 69(23):3895-909 PMID: 22562579
- 5. Shizu R et al.. 2017. Phosphorylated Nuclear Receptor CAR Forms a Homodimer To Repress Its Constitutive Activity for Ligand Activation.. Mol Cell Biol 37(10) PMID: 28265001
- 6. Zolin IA et al.. 2025. MLE/DHX9 without Helicase Activity Activates Constitutive Expression of Nuclear Receptor Genes in Drosophila melanogaster.. Dokl Biochem Biophys 525(1):527-531 PMID: 41329267
- 7. Liu J et al.. 2025. Muscle Rev-erb controls time-dependent adaptations to chronic exercise in mice.. Nat Commun 16(1):5708 PMID: 40593528
- 8. Savkur RS et al.. 2004. Pharmacology of nuclear receptor-coregulator recognition.. Vitam Horm 68:145-83 PMID: 15193454
